Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Innoviva (INVA) EBITDA (2016 - 2026)

Innoviva filings provide 16 years of EBITDA readings, the most recent being $34.6 million for Q3 2025.

  • On a quarterly basis, EBITDA fell 20.03% to $34.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $64.6 million, a 20.36% decrease, with the full-year FY2025 number at $163.7 million, down 1.87% from a year prior.
  • EBITDA hit $34.6 million in Q3 2025 for Innoviva, down from $48.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $96.5 million in Q2 2021 to a low of -$11.3 million in Q1 2023.
  • Median EBITDA over the past 5 years was -$6.0 million (2021), compared with a mean of $18.5 million.
  • Biggest five-year swings in EBITDA: plummeted 109.55% in 2022 and later surged 1515300.0% in 2023.
  • Innoviva's EBITDA stood at -$6.0 million in 2021, then tumbled by 70.77% to -$10.3 million in 2022, then soared by 36.31% to -$6.6 million in 2023, then tumbled by 60.22% to -$10.5 million in 2024, then skyrocketed by 428.1% to $34.6 million in 2025.
  • The last three reported values for EBITDA were $34.6 million (Q3 2025), $48.8 million (Q2 2025), and -$8.2 million (Q1 2025) per Business Quant data.